SCHEMBL3012864

SCHEMBL3012864

Cc1cc(S(=O)(=O)C2CCN(c3nc(Cc4cc(F)cc(F)c4)cs3)CC2)c(Cl)cc1Cl

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.34
CHRM5 P08912 1/20 0.34
MAPK1 P28482 1/20 0.32
DNM1L O00429 5/20 0.32
HRH3 Q9Y5N1 1/20 0.32
LMNA P02545 2/20 0.32
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
SMO Q99835 1/20 0.31
MAPT P10636 2/20 0.30
USP2 O75604 1/20 0.30
RECQL P46063 1/20 0.30
HSD17B10 Q99714 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013479 0.96 CTSS (0.33) CTSSCHRM5MAPK1DNM1LHRH3
SCHEMBL3007705 0.92 CHRM5 (0.35) CHRM5MAPK1DNM1LHRH3LMNA
SCHEMBL3015088 0.91 CHRM5 (0.35) CHRM5DNM1LHRH3LMNACNR1
SCHEMBL3003947 0.89 CACNA1G (0.37) CTSSCHRM5MAPK1DNM1LHRH3
SCHEMBL3018847 0.89 SOS1 (0.37) CTSSCHRM5DNM1LLMNACNR1
SCHEMBL3007781 0.89 PROKR1 (0.38) CTSSCHRM5DNM1LHRH3LMNA
SCHEMBL3012261 0.88 LMNA (0.40) CHRM5MAPK1DNM1LLMNAALDH1A1
SCHEMBL3003075 0.88 MAPT (0.36) CHRM5MAPK1LMNASMN1; SMN2CNR1
SCHEMBL3016337 0.88 SMN1; SMN2 (0.36) CHRM5DNM1LLMNAALDH1A1SMN1; SMN2
SCHEMBL3015804 0.88 SMN1; SMN2 (0.39) CHRM5MAPK1LMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885CHRM5 4145/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.